Arabinoxylan oligosaccharides (AXOS) are studied as food compounds with prebiotic potential. Here, the impact of consumption of breads with in situ-produced AXOS on intestinal fermentation and overall gastrointestinal characteristics was evaluated in a completely randomized, double-blind, controlled, cross-over study. Twenty-seven healthy volunteers consumed 180 g of wheat/rye bread with or without in situ-produced AXOS (WR + and WR 2 , respectively) daily for 3 wk.
Introduction
AX 11 , which consists of a linear backbone of (1/4)-linked b-Dxylopyranose units with L-arabinofuranose as the main substituent, is one of the major dietary fiber fractions in cereals like wheat (1) . However, AX content in grains varies largely within the layer of the kernel, because AX makes up 15-30% of the bran layers, whereas wheat endosperm contains only 1-3% AX (2) . Typically, only a minor part of AX is WE-AX (3). WU-AX is poorly degraded in the colon and hence may, like other insoluble fibers, increase bowel mass and fasten transit of chyme through the gut (4) . Conversely, WE-AX is readily fermented and its effect has been associated with a reduced intestinal pH, lower levels of proteolytic catabolites, and improved glucose and lipid metabolism (5, 6) . In general, a reduction of the pH in the large bowel, due to the formation of SCFA, the primary fermentation products of carbohydrates, is considered beneficial, because it may prevent the growth of some malignant bacteria (7) . In addition, acidification of the large bowel may also impair the production of protein degradation products, of which some have shown to be carcinogenic in vitro (8) .
In recent years, cereal AX have gained further interest, because their hydrolysis products, AXOS, have been proposed as food compounds with prebiotic potential (9) . Prebiotics were first defined by Gibson et al. (10) as nondigestible food ingredients, often oligosaccharides, that contribute to consumers' well-being by selectively stimulating the growth and/or activity of beneficial bacteria in the gut. To date, an array of studies support the hypothesis that AXOS can be classified as food components with prebiotic potential (9) . It was suggested that the selective bifidogenic effect of AXOS is closely related to their avDP, because levels of bifidobacteria increase with lower avDP of AXOS (6) . Today, the term AXOS is typically reserved for hydrolyzed AX with an avDP between 5 and 50 (11) . The positive impact of AXOS on intestinal fermentation was confirmed in clinical studies. Daily intake of 10.0 g of AXOS by healthy volunteers is well tolerated and promotes bifidobacterial growth in the colon while suppressing the excretion of urinary p-cresol, a potentially harmful catabolite of protein fermentation (12) . Additionally, Cloetens et al. (8) indicated that consumption of AXOS at doses as low as 2.2 g is associated with a marked shift from urinary to fecal 15 N excretion. Currently, the production of AXOS is mainly performed at pilot scale by enzymatic hydrolysis of AX with wheat bran as a low-cost starting material (13) . However, a method was recently established to produce AXOS in situ at high levels in fiber-rich breads through addition to the dough of a xylanase mixture comprising at least one thermophylic xylanase (11, 14) . Given the status of bread as a staple food in the Western world with, e.g., an average consumption of 180 g/d in Western Europe (15) , this technology would ensure the daily intake of AXOS at levels .2.0 g and with an avDP between 5 and 50 (11, 14) . Moreover, thermophilic xylanase-mediated transformation of a substantial part of the AX population in fiberenriched bread leads to the presence of different types of AX, in particular WU-AX and AXOS. A recent study on rats demonstrated that a combination of different types of AX synergistically enhanced putative markers associated with colonic health (16) .
This study aimed to investigate whether intake of wheat/rye bread enriched in in situ-produced AXOS by healthy volunteers has an effect on carbohydrate and protein fermentation products and whether it alters the levels of microbiota in the feces, in particular fecal bifidobacteria, both hallmarks of prebiotic potential. In addition, the effect of intake of such bread on average stool frequency and consistency as well as on possible adverse gastrointestinal symptoms was assessed. The experimental setup equally allowed us to assess the impact of intake of rye enriched bread compared to wheat bread on these end points.
Methods

Participants
A total of 27 volunteers [17 women and 10 men, median age 25 (IQR [23] [24] [25] [26] [27] [28] [29] ], median BMI of 20.9 kg/m 2 (IQR 20.0-23.7) participated in the study. Inclusion criteria were: age between 18 and 46 y, good general health (determined by self-assessment), and regular eating habits (3 meals/d).
Exclusion criteria were: history of abdominal surgery, intake of antibiotics ,2 mo before the start of the study, and medical treatments influencing gut transit ,2 wk before the start of the study. During the study, the volunteers were allowed to maintain their usual diets, except for the required intake of the supplied bread slices. At recruitment, the volunteers were informed about the pre-and probiotic concept and food substances containing pre-and/or probiotics.
The present study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human participants were approved by the Ethics Committee (Institutional Review Board) of the University of Leuven. Written informed consent was obtained from all participants.
Materials
Refined wheat flour (Surbi) was from Dossche Mills and Bakery. Rye whole-grain meal (Type 1740) was from Plange Mü hle. Rye bran was provided by Paniflower. Baker's yeast was from Algist Bruggeman.
Gluten was obtained from Syral. The xylanase-free bread improver mix, providing 1.0 g of a-amylase (Bel'Ase A75), 15.0 g ascorbic acid, and 300 g di-acetyl tartaric acid ester of monoglyceride/100 kg total flour mixture, was from Puratos Group. The xylanase preparation with an activity of 2100 MU/L was from Puratos Group. Termamyl 120L, a thermostable amylase preparation, was from Novozymes.
All solvents, chemicals, and reagents were of at least analytical grade and purchased from Sigma-Aldrich unless otherwise specified.
Production and characterization of the investigational products
Bread making. W 2 was prepared by mixing 592.0 g wheat flour with 11.8 g of salt, 11.8 g of baker's yeast, 11.8 g of xylanase-free bread improver mix, 17.8 g of gluten, and 355.0 mL water per kg total dough mix. WR 2 was prepared by mixing 430.0 g wheat flour with 100.0 g rye whole meal, 43.0 g rye bran, 11.5 g of salt, 11.5 g of baker's yeast, 11.5 g of xylanase-free bread improver mix, 17.2 g of gluten, and 375.0 mL of water per kg dough. WR + was prepared as WR 2 except that the baking absorption was reduced to 374 mL of water/kg total mix, and that the xylanase preparation (1.0 mL) was added.
After mixing, the doughs were divided into pieces of 820 g each, manually rounded, and allowed to rise at room temperature for 20 min, followed by mechanical molding, panning, and proofing (90 min at 358C and 95% relative humidity). Doughs were baked in a hot-air oven at 2308C for 35 min. The breads were sliced 2.5 h after baking, packaged in polypropylene bags in rations of 180 g/pack, and frozen at 2208C until consumption by the volunteers. All breads were prepared and packed at Puratos Group.
Compositional analyses. Bread slices from the middle of the loaf were dried (1058C, 12 h), followed by cooling to room temperature in an exsiccator for 1 h. The dried bread slices were homogenized using mortar and pestle to yield a dried bread powder.
Moisture and ash contents were analyzed according to American Association of Cereal Chemists. International methods 44-19 and 08-01, respectively (17) . Protein contents were determined according to the Dumas combustion method as described earlier (6) . Lipid content was determined by the Soxhlet method according to AOAC Official Method 945.16 (18) . Fiber was determined by AOAC Official Method 2001.03 (18) .
For characterization of the AX population and starch content, aqueous extracts of breads were prepared by mixing dried and ground bread (2.00 g) with water (20 mL) and Termamyl 120L (120 mL) pretreated for 1 h at 908C prior to use to destroy possible enzyme activities other than amylase activity. The suspension was incubated under constant shaking (378C, 30 min) and subsequently centrifuged (3000 3 g, 48C, 15 min). The supernatant was stored at 2208C until further analysis. Total hydrolysable carbohydrate content of breads and total and reducing end saccharide contents of aqueous extracts thereof were measured by GC as described by Courtin et al. (19) . The total AX content of bread was calculated using formula 1. The WE-AX/AXOS content and the avDP of WE-AX/AXOS was calculated using formulae 2 and 3, respectively. The starch content of bread was calculated using formula 4.
Total AX ð%Þ ¼ ð%arabinose in dried bread20:73%galactose in bread extractÞ3132=150þ½1323ðavDP À 1Þþ150=½1503avDP 3%xylose in bread WE-AX=AXOSð%Þ ¼ ð%arabinose in bread extract20:7 3%galactose in bread extractÞ 3 132=150 þ ½1323ðavDP-1Þ þ150=½150 x avDP 3 %xylose in bread extract avDP ofWE-AX=AXOS ¼ ð%arabinose in bread extract20:7 3%galactose in bread extract þ %xylose in bread extractÞ= %reducing end xylose in bread extract starch ¼ 0:9 3 ð%glucose in dried breadÞ:
The formulae 1, 2, and 3 contain a correction for the galactose present in aqueous extracts under the form of wheat and rye water-extractable arabinogalactan peptides with an arabinose:galactose ratio of 0.7 (20) . The factors 132 and 150 in formulae 1 and 2 reflect the molecular mass of anhydropentose sugars and pentose sugars, respectively.
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Study design
The total treatment period of the randomized, double-blind, controlled, cross-over trial was 12 wk divided over four consecutive periods of 3 wk each (Fig. 1) . The run-in and/or wash-out periods prior to the WR + and WR 2 treatment periods were denoted as preWR + and pre WR 2 period, respectively. During these periods, W 2 was consumed by the participants. Throughout the study, 180 g fresh weight of the provided bread was consumed on a daily basis, which is close to the average daily bread intake in a number of representative Western European countries (15) . The packages with frozen bread slices were supplied by members of the investigational staff to the volunteers once per week or more frequently, depending on the freezer capacity at home of the volunteer.
From the morning of d 19 of each intake period, all participants collected urine for 48 h. A stool sample was collected on the evening of d 20 or morning of d 21 of each intake period. During the final week of each intake period, participants completed a questionnaire about defecation frequency, stool consistency [Bristol Stool Score (21)], and possible gastrointestinal symptoms. Upon delivery of samples, compliance with investigational product consumption was evaluated by participant interview. Participants were requested to record any noncompliance throughout the study, including the amount of bread not consumed per day.
Sample collection
Stool samples. Stool samples were stored immediately after defecation at 48C and delivered at the collection point within 16 h. Upon delivery, 2.5 g of each stool sample was immediately fixed in paraformaldehyde (22) for microbial analysis by FISH. Fresh stool samples (;2.50 g) were freeze-dried and dry matter content was determined as an indicator for stool consistency. Aliquots of 2.0 g feces were stored at 2208C until further analysis of SCFA.
Urine samples. Urine was collected for 48 h in dedicated containers (5 L) to which 1.0 g neomycine was added to prevent bacterial growth (8) . The volume of the urine fractions was measured and aliquots (20 mL) were stored at 2208C until further analysis.
Analytical procedures
SCFA analysis in feces. SCFA were extracted with diethyl ether and analyzed with GC as described by Van Craeyveld et al. (6) . The total SCFA concentration was calculated as the sum of the concentrations of acetic, propionic, and butyric acids.
Phenol and p-cresol in urine. Total phenol and p-cresol content in urine samples was assayed by GC-MS as described by de Loor et al. (23) . The GC was equipped with a RxiTM-5MS column (Restek, 30 m 3 0.25 mm, 0.50-mm film thickness). Helium was used as carrier gas with constant flow of 1.3 mL/min. The oven was programmed from 558C (isothermal for 5 min) and increased by 108C/min to 1608C and by 208C/ min to 2808C. Mass spectrometric detection was performed in electron impact full scan mode from m/z 59 to 590 at two scans/s.
Microbiological analysis of feces. FISH was used to count the number of different bacterial groups in paraformaldehyde-fixed stool samples. Processing of fixed samples and FISH analysis were performed as described by Langendijk et al. (24) . For total bacteria cell counts, 49-6-diamidino-2-phenylindole was used. The probes used for group-specific analyses were Bif164 for Bifidobacterium species (24), Lac158 for Lactobacillus species (25), Ec1531 for enterobacteria (26) , and an equimolar mixture of Chris150 and Clit135 for the Clostridium histolyticum/lituseburense group (22) . Rod-shaped bacteria fluorescing with the Lac158 probe were scored as Lactobacillus rods. Fluorescent cells were counted by using Quantimet HR600 image analysis software (Leica). The detection limit of the log 10 counts by the FISH procedure was 5.65 log 10 /g wet feces and values below the detection limit were set to one-half the detection limit.
Recording of stool characteristics and gastrointestinal symptoms. During the last week of each intake period, participants were requested to daily evaluate following symptoms: abdominal cramps, flatulence, and bloating. The severity of the symptoms was graded on a 4-step scale ranging from no (0) to severe (4) symptoms as described by van Munster et al. (27) . Defecation frequency and consistency of the stool according to the Bristol Stool Form Scale (21) were recorded daily through appropriate questionnaires. The average stool frequency was calculated as the number of stools divided by the number of days of diary recording, whereas the average stool consistency corresponded to the sum of Bristol Stool Form Scales divided by the number of stools. Finally, the composite factor of stool frequency and consistency was defined as the sum of Bristol Stool Form Scales divided by the number of days of diary recording (28) .
Statistics
A statistical analysis plan was made available prior to the review and statistical analysis of the study data by an external biostatistician, who had no links to either sponsor or institution of the principal investigator and who was not involved in the execution of the clinical trial.
The EE population was defined as all randomized participants who received control treatment (WR 2 ) and at least one serving of investigated treatment (WR + ) and provided at least one postrandomization outcome data point during each of the two treatment phases. In the PP population, participants with major protocol violations were excluded. No imputation for missing data was performed.
Outlyingness of data was checked using box plots marking all data that were smaller than the 25th quartile 2 1.5 3 IQR or .75th quartile + 1.5 3 IQR. All outlier data were checked for possible errors and biological significance. All the available data points were kept for further statistical analysis.
Nonparametric tests (Kruskall-Wallis) were used for the analysis of differences at baseline for age and length. All other outcome parameters, whether the outcomes were rank transformed or not, were analyzed using a parametric linear mixed model and inference on the treatment comparisons was done using tests for general parametric models.
To test for differences at baseline, the treatment sequence groups were compared with respect to age, gender, and BMI, the only relevant initial factors recorded at baseline in this study. , and WR + period) of 3 wk each. Participants (n = 27) were randomly divided into two groups. All volunteers collected urine (48 h) and feces samples at the end of each 3-wk intake period. The participants also completed a diary questionnaire about stool frequency, stool consistency, and gastrointestinal symptoms during the last week of each 3-wk intake period. W 2 , without in situ-produced arabinoxylan oligosaccharides; WR + , wheat/rye bread with in situ-produced arabinoxylan oligosaccharides; WR 2 , wheat/rye bread without in situ-produced arabinoxylan oligosaccharides.
groups
used to check baseline differences. Gender differences were tested using the chi-square test or, in case there were not enough data in each cell of the contingency table, the Fisher Exact test.
The treatment effect for the different outcome variables was analyzed using a linear mixed model (29) . The fitted model included participant as a random effect and contained terms for treatment and treatment sequence. Because the spread of the inclusion period for all participants was only 1 wk, no term for inclusion period was used in the linear mixed models.
To test the validity of the linear mixed models, the normality of the residuals was checked with the Shapiro-Wilk test (30) . In case this test rejected the null hypothesis of normality of the residuals at a Type I error rate of a = 0.01, the dependent variable was rank-transformed and the linear mixed model was performed on the rank-transformed data (31) . Ties occurring during the rank transformation were replaced with their mean rank. For each linear model, whether based on raw data or rank-transformed data, interactions were tested between treatment and treatment sequence. Treatment effects as well as treatment 3 treatment sequence interaction effects were tested using conditional Fand t tests (29) .
In case no significant interactions were found, treatment differences were evaluated based on the main effect model. For these models, pairwise multiple comparisons were executed to compare the difference between the parameter at the treatment period and at the immediately preceding run-in of wash-out period and the difference between the parameters at the two treatment periods.
In case of models with interactions, the above-mentioned pairwise comparisons were made for each treatment sequence group. Next to that, the overall differences were also analyzed by aggregating over the interaction effects in the model.
The Bonferroni procedure was used to correct for all pairwise multiple comparisons and reported P values were adjusted accordingly.
Results
Participant characteristics A total of 33 volunteers were screened and 28 were randomized to either one of the two groups differing in treatment sequence (n = 13 and 15, respectively) (Supplemental Fig. 1 ). One volunteer was asked to prematurely terminate the study due to noncompliance, because this volunteer frequently missed appointments. This volunteer did not receive the control treatment and was not included in the EE population. Hence, 27 volunteers were included in the EE population. Because no major protocol violations were reported for these 27 volunteers, the PP population was the same as the EE population. In the EE/PP population, treatment sequence group 1 consisted of 13 volunteers and treatment sequence group 2 consisted of 14 volunteers.
Sex, age, and BMI did not significantly differ at baseline between the two treatment sequence groups.
Compositional analysis of applied bread types WR 2 and WR + contained similar amounts of total fiber ( Table 1) . The low-molecular weight fiber content of WR + was higher than that of WR 2 . Xylanase treatment in WR + resulted in an AXOS level corresponding to one-half of the total AX population, with an avDP of 18 ( Table 1 ). The avDP of WE2AX/AXOS in W 2 and WR 2 were 174 and 212, respectively.
Study compliance The number of nonconsumed bread slices was low, with a mean of 1.4, 1.6, 1.0, and 1.2% during the preWR + , WR + , pre WR 2 , and WR 2 periods, respectively. There were no differences observed between the treatments (P . 0.10). Table 2 ). The fecal total SCFA concentration was higher after the WR + than during the preWR + period (P = 0.02). Fecal concentrations of acetate and propionate in the WR + period tended to be higher (P , 0.1) compared with the preWR + period. Intake of WR + resulted in higher (P = 0.02) fecal butyric acid levels than those observed at the end of the preWR + period. Neither fecal acetate, fecal propionate, nor fecal butyrate levels differed significantly at the end of the WR 2 and pre WR 2 periods.
SCFA in feces
Phenol and p-cresol in urine Urinary phenol and p-cresol excretions were lower after the WR + than after the WR 2 period (P # 0.05) ( Table 3) . At the end of the WR 2 period, urinary phenol excretion was higher (P = 0.04) and that of p-cresol tended to be higher (P = 0.09) than during the pre WR 2 period. Urinary excretions of phenol and p-cresol did not differ between the preWR + and WR + periods.
Microbiological analysis of feces Total bacteria numbers were unaffected by administration of WR 2 or WR + (Supplemental Table 1 ). Fecal bifidobacteria counts, however, tended to be higher at the end of the WR + period compared to the preWR + period (P = 0.06). Similar to total bacteria, levels of lactobacilli, rod-shaped lactobacilli, Enterobacteriaceae, and bacteria belonging to the C. histolyticum/lituseburense group were not affected by the treatments (Supplemental Table 1 ).
Stool characteristics and gastrointestinal symptoms
The stool frequency increased (P = 0.02) in the WR + period relative to the WR 2 period (Table 4) . Stool consistency did not differ after the WR + and WR 2 periods. The composite factor for stool frequency/consistency was higher (P = 0.001) after 3-wk consumption of WR + compared to WR 2 . Abdominal cramping and bloating were virtually absent throughout the study and did not differ during wk 3 of the treatment periods (data not shown). Flatulence symptoms 
Discussion
The present double-blind, cross-over study investigated the effects of consumption of xylanase-treated and untreated wheat/ rye breads on putative markers of colonic health. The specific impact of xylanase treatment during wheat/rye bread making, resulting in the presence of wheat-and rye-derived AXOS, was assessed by comparing the gastrointestinal effects induced after 3-wk consumption of AXOS-rich wheat/rye bread with those observed after the intake of their xylanase-untreated counterparts (WR 2 ). In addition, the potentially beneficial role of incorporation of dietary fiber as such, in bread, was investigated by comparing the effect of the consumption of WR 2 with intake of control wheat bread without rye fiber (W 2 ). Finally, any combined effect of xylanase treatment and rye incorporation was analyzed by comparing the effect of WR + consumption with the effect observed after intake of the control wheat bread (W 2 ).
Carbohydrate fermentation. Consumption of WR + increased the fecal total SCFA concentration compared to the intake of W 2 in the run-in and wash-out periods (P = 0.02). In general, it can be expected that partial replacement of wheat flour by fiberrich whole-grain rye meal and rye bran enhances SCFA production, because these fiber-rich ingredients provide high levels of undigestible carbohydrates (32) . However, fecal concentrations of SCFA remained unaffected after 3-wk intake of WR 2 . Therefore, the SCFA-boosting effect of WR + must be ascribed mainly to the partial conversion of wheat and rye AX into AXOS, taking into account that AXOS is more fermentable in the colon than WU-AX and WE-AX.
Whereas intake of WR + tended to promote the formation of acetate and propionate, the higher fecal SCFA concentrations at the end of the WR + period were due to an intensive stimulation of butyrate production.
From a digestive health perspective, butyrate production is considered relevant, because it is generally acknowledged to play a key role in maintenance of homeostasis in the colon (33, 34) . Unlike the present results, most studies on the intake of fructans and galactooligosaccharides fail to observe an effect on fecal SCFA concentrations (35) (36) (37) .
Interestingly, it was recently shown that a 1:1 combination of WU-AX and AXOS, as was obtained in WR + , synergistically promotes the production of butyrate in the cecum of rats (16) . The stimulatory effect of AXOS on butyrate formation was explained by the fact that acetate, which is by far the primary metabolite of AXOS fermentation, is readily converted to butyrate by the many butyrogenic species present in the colon and their stimulation by the presence of WU-AX (38) . Alternatively, it can be envisaged that AXOS stimulates xylanase production by butyrogenic bacterial species, allowing them to better ferment WE-AX and/or WU-AX.
Phenol and p-cresol excretion. Consumption of WR + suppressed the urinary excretions of potentially detrimental phenol and p-cresol compared to the intake of WR 2 . The urinary excretion of phenols may give a good indication of colonic bacterial protein metabolism, because it has been established that under steady-state conditions, urinary excretion of phenolic compounds reflects their generation in the colon as bacterial catabolites of phenylalanine and tyrosine (39) . In accordance with the present results, Cloetens et al. (12) observed a decreased excretion of p-cresol after daily administration of 10 g AXOS during 3 wk. It can be expected that a shift of the metabolic and microbiological intestinal balance induced by fermentable substrates like AXOS contributes to lower proteolytic activity. In this respect, enhanced bacterial growth, reduction of the pH, and repression of proteases transcription are all considered carbohydrate-driven mechanisms that stimulate N-uptake or lower the activity of proteolytic enzymes in the hindgut (40) . Compared with W 2 , intake of WR + did not significantly reduce the urinary excretions of phenolic compounds. However, consumption of WR 2 resulted in a higher excretion of phenol compared to the preceding wash-out or run-in period.
Due to its physico-chemical effects, fiber can reduce the uptake of nutrients in the small intestine and can, in turn, increase the availability of these substrates through fermentation in the hindgut. In addition, it can be reasoned that part of the proteins in the applied fiber-rich preparations are tightly bound to the fibrous matrix. Therefore, they may be inaccessible for digestion yet released upon fermentation in the colon. Xylanase treatment, however, may enhance the accessibility of such proteins by solubilizing and degrading part of the AX. The xylanase treatment applied in the production of WR + may counteract the increase in proteolytic activity observed in WR 2 , thus leading to a neutral effect relative to W 2 .
Microbiological growth. While there were no significant differences in bacterial growth during the different treatment periods, consumption of WR + did tend to increase fecal levels of bifidobacteria relative to consumption of W 2 in the preceding run-in or wash-out period (P = 0.06). Because the levels of other bacterial groups in the feces remain unaffected, any growthpromoting potential of WR + appears to be selective, as expected for prebiotics (10) . Although intake of AXOS-enriched breads only tended to change the microbial composition in the gut, results suggest that both the presence of AX rich substrates and their degradation by xylanase during bread making is required to yield breads with a selectively bifidogenic growth-promoting potential (P = 0.06). This is consistent with results by Cloetens et al. (41) , who reported that upon consumption of AXOS with an avDP of 15 and 9, respectively, only the latter provoked a bifidogenic effect in humans. Van Craeyveld et al. (6) equally showed that the bifidogenic effect of AXOS largely depends on their avDP, because particularly AXOS with low avDP promoted the growth of bifidobacteria. In this regard, it was hypothesized that some bifidobacteria can take up small oligosaccharides but are unable to hydrolyze larger polymers, because they do not possess the required xylanase enzymes (9) . Selective stimulation of colonic bifidobacteria may be related to reduced gut infections, inflammation, and lower prevalence of colon cancer initiation (42) .
Stool and gastrointestinal symptoms. Consumption of WR + resulted in a higher stool frequency anda distinctly higher composite stool frequency/consistency factor compared to WR 2 . This possibly points to a faster stool transit upon intake of WR + compared to WR 2 (43), thus suggesting that consumption of AXOS-enriched bread (WR + ) is more beneficial for improving gastrointestinal transit than consumption of the corresponding bread in which the AX is not partially depolymerized. However, because consumption of WR + and W 2 had similar effects on stool frequency and consistency, it can be concluded that a clear effect of rye incorporation combined with xylanase treatment on stool characteristics was absent. In general, softer stools and a reduced gastrointestinal transit time upon fiber intake is often ascribed to its bulking effect and water-binding capacity (4). These physico-chemical effects are typically less pronounced in case of soluble fibers compared to insoluble fibers, because they are more prone to fermentation. Conversely, they may also contribute to softer stools by increasing bacterial biomass and host secretions, e.g., mucin.
Finally, consumption of WR + had no effect on the assessed gastrointestinal symptoms, abdominal cramps, flatulence, and abdominal bloating, indicating that it is well tolerated by the volunteers (P . 0.1).
In conclusion, the intake of AXOS-rich wheat/rye bread at levels similar to the average daily bread intake noted in Western Europe may alter gastrointestinal fermentation characteristics relative to xylanase-untreated wheat bread and xylanase-untreated wheat/rye bread. Compared with consumption of wheat bread without AXOS, significantly higher total SCFA concentrations were observed in the feces of healthy participants after intake of AXOS-enriched wheat/rye bread. The increase in SCFA concentrations was largely attributed to an elevated production of butyrate, a SCFA of particular interest from a digestive health perspective. Conversely to xylanase untreated wheat/rye breads, consumption of their xylanase-treated counterparts did not increase the concentrations of phenolic compounds in urine. Moreover, a trend (P = Gastrointestinal effects of in situ-formed arabinoxylan oligosaccharides 475 0.06) toward higher fecal bifidobacteria was observed after intake of AXOS-rich wheat/rye bread compared to consumption of xylanase-untreated wheat bread. Finally, this study showed that the consumption of AXOS-enriched wheat/rye bread is well-tolerated, because no adverse gastrointestinal symptoms were reported.
